Milne-Ives Madison, Lam Ching, van Velthoven Michelle, Meinert Edward
Digitally Enabled PrevenTative Health Research Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
Department of Primary Care and Public Health, Imperial College London, London, United Kingdom.
JMIR Res Protoc. 2020 Sep 23;9(9):e17684. doi: 10.2196/17684.
The continuing uncertainty around Brexit has caused concern in the pharmaceutical industry and among health care professionals and patients. The exact consequences of Brexit on the pharmaceutical supply chain in the United Kingdom will depend on whether a deal is reached and what it entails, but it is likely to be affected by the withdrawal of the United Kingdom from the European Union. Regulatory issues and delays in supply have the potential to negatively affect the ability of UK residents to receive an adequate and timely supply of necessary medicines.
The purpose of this protocol is to provide an overview and critical analysis of current perspectives on the effect of Brexit on the UK pharmaceutical supply chain.
The PRISMA-ScR (Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews) guidelines will be used to structure this protocol. A systematic search of MEDLINE, EMBASE, PsycINFO, Healthcare Management Information Consortium (HMIC), Cochrane, Web of Science, Business Source Complete, EconLit, and Economist Intelligence Unit will be conducted, as well as a Google and Nexis.UK search for grey literature such as reports, opinion pieces, and press releases. Two reviewers will independently screen the titles and abstracts of identified references and select studies according to the eligibility criteria. Any discrepancies will then be discussed and resolved. One reviewer will extract data from the included studies into a standardized form, which will be validated by a second reviewer. Risk of bias will be assessed using the Cochrane Collaboration Risk of Bias tool for any randomized controlled trials; quality will be assessed using the relevant Critical Appraisal Skills Programme (CASP) checklists; and grey literature will be assessed using the Authority, Accuracy, Coverage, Objectivity, Date, Significance (AACODS) checklist. Outcomes include the agreement between sources on the potential, likelihood, and severity of the consequences of Brexit on the UK pharmaceutical supply chain.
Results will be included in the scoping review, which will be published in 2020.
This scoping review will summarize the currently expected consequences of Brexit on the UK pharmaceutical supply chain.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/17684.
英国脱欧的不确定性持续存在，引发了制药行业、医疗保健专业人员及患者的担忧。英国脱欧对英国药品供应链的确切影响将取决于是否达成协议及其具体内容，但很可能会受到英国退出欧盟的影响。监管问题和供应延迟有可能对英国居民及时获得充足必要药品的能力产生负面影响。
本方案旨在概述并批判性分析当前关于英国脱欧对英国药品供应链影响的观点。
将使用PRISMA-ScR（系统评价和Meta分析扩展版的范围综述优先报告项目）指南来构建本方案。将对MEDLINE、EMBASE、PsycINFO、医疗保健管理信息联盟（HMIC）、Cochrane、科学网、商业资源完整版、EconLit和经济学人智库进行系统检索，并在谷歌和Nexis.UK上搜索灰色文献，如报告、评论文章和新闻稿。两名评审员将独立筛选已识别参考文献的标题和摘要，并根据纳入标准选择研究。然后将讨论并解决任何差异。一名评审员将把纳入研究的数据提取到标准化表格中，由另一名评审员进行验证。对于任何随机对照试验，将使用Cochrane协作偏倚风险工具评估偏倚风险；将使用相关的批判性评价技能计划（CASP）清单评估质量；将使用权威性、准确性、覆盖范围、客观性、日期、重要性（AACODS）清单评估灰色文献。结果包括不同来源在英国脱欧对英国药品供应链影响的可能性、可能性程度和严重程度方面的一致性。
结果将纳入范围综述，并将于2020年发表。
本范围综述将总结英国脱欧目前对英国药品供应链的预期影响。
国际注册报告识别号（IRRID）：PRR1-10.2196/17684
